BioCentury
ARTICLE | Clinical News

AKB-9778: Completed Phase II enrollment

December 15, 2014 8:00 AM UTC

Aerpio completed enrollment of 144 patients in the double-blind, placebo-controlled, U.S. Phase II TIME-2 trial comparing 15 mg subcutaneous AKB-9778 twice daily with and without monthly Lucentis ran...